Organizing committee invites all participants from all over the world to attend “10th World Congress on Rare Diseases and Orphan Drugs’’ during July 22-23, 2020 Barcelona, Spain.

A rare disease is a health condition that affects a small number of people compared with other prevalent diseases in the general population.  They are characterized by a wide diversity of disorders and symptoms that differs not only from disease to disease but also from individual to individual patient suffering from the same disease. About 80% of these disorders have predictable genetic origins while the others are the result of infections, allergies, neurological related and environmental causes. A medicinal product developed for the treatment of a Rare Disease is an Orphan Drug. Under regular market environments the pharmaceutical industry has little attention in evolving and marketing products of Orphan Drugs proposed for only a small number of patients.

Why to attend???

• Hear about the latest research.
• Improve your presentation and communication skills.
• Get response on an early version of your latest work.
• Acquire beyond your field or interest.
• Get opportunity to people to meet you.
• Know the strengths and weakness of your conferences.
• Easier to solve the problems and struggles which you go through at work.

Target Audience:

• Infectious Diseases Specialist
• Scientists
• Researches
• Students
• Medical devices manufacturing companies
• Health care professionals
• Pharmaceutical companies
• Neurologists
• Virologists
• Pathologists
• Orphan drug companies
• Patient groups

Market Growth of Rare Diseases :

Nearly there are 7,000 different types of Rare Diseases and disorders it has estimated that 30 million people in the United States, 30 million in Europe and 350 million people over the globe suffer from Rare Diseases. Four by fifth of Rare Diseases are genetic in origin, among them affected individuals 50% of them will be children. The Rare Diseases are distributed in such a way that four fifth of the cases accounted by some 350 Rare Diseases. About only 5% of rare diseases are having approved drug treatment with only 326 new drugs being approved from the FDA and brought in to the market.

In 2018, Orphan Drug sales were of the order of 93 billion. Orphan Drugs represented 35% of the industry’s new drug approvals. The genetic diseases are subdivided by therapeutic area, which was leading the global market in the past will show similar traction in the coming next eight years. This segment is anticipated to be valued at US$ 56,241 by the end of 2025. According to Statistics of MRC, the Global Orphan Drug market is estimated at $145.89 million in 2018 and is expected to reach $265.63 million by 2022 growing at a CAGR of 10.5% from 2018 to 2022.market is expected to grow significantly in emerging economies during the forecast period.

Best Regards         
Bella Christine | Program Director        
Conference Short Name: Rare Diseases Congress 2020     
Contact Number: 442838022009
Email:  rarediseases@brainstormingmeetings.com
Website: https://rarediseases.insightconferences.com/